sFlt1 levels increase before and during the advent of signs and symptoms of preeclampsia. sFlt1 is a splice variant of vascular endothelial growth factor receptor 1 (VEGF-R1) and is capable of acting as a molecular sink to decrease active VEGF and placental growth factor (PIGF). Animal models suggest that sFlt1 plays a pivotal role in the pathogenesis of preeclampsia. Studies using apheresis to lower sFlt1 levels in patients are currently underway.
S. Ananth Karumanchi, MD is a Professor of Medicine at Beth Israel Deaconess Medical Center and Harvard Medical School, Boston. He currently works as an attending physician [...]
The Final Four Sudden Cardiac Death in ESRD vs Furosemide Stress Test Winner: Sudden Cardiac Death in ESRD 4-3 split With the narrowest of margins Team Sudden Cardiac Death [...]
The Elite 8 is the final four of our tournament. In the NCAA tournament the final four represent the four regional winners. In NephMadness the Elite eight represent the 8 [...]
sFlt1 in Preeclampsia vs ACOG BP Goal <160/110 in Preeclampsia sFlt1 in Preeclampsia 6-1 split sFlt1 holds promise not just as a diagnostic test but as a possible [...]
See the Current Standings! | For more on NephMadness 2015 | #NephMadness or #OBRegion on Twitter The Obstetric and Nephrology Region was a mixture of routes and close games. [...]
Submit your picks! | For more on NephMadness 2015 | #NephMadness or #OBRegion on Twitter The most intense and emotional moments one can have as a nephrologist are centered [...]